Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus

Journal of Medical Virology

Volumn 68, Issue 3, 2002, Pages 311-318

  Wakil, Salma M ^a,c,d   Kazim, Syed N ^a,b,d   Khan, Luqman A ^b   Raisuddin, Sheikh ^c   Parvez, Mohammad K ^a,b,d   Guptan, Rajkumar C ^a   Thakur, Varsha ^a   Hasnain, Seyed E ^d,e   Sarin, Shiv K ^a  

^a G B PANT HOSPITAL   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

^c HAMDARD UNIVERSITY   (India)

^d NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^e CENTRE FOR DNA FINGERPRINTING AND DIAGNOSTICS   (India)

Author keywords

Chronic hepatitis; Hepatitis B virus; Lamivudine resistance; Mutations; Polymerase gene; Surface gene; YMDD

Indexed keywords

LAMIVUDINE;

ADULT; ARTICLE; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CHRONIC HEPATITIS; DRUG EFFECT; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PREVALENCE; STOP CODON; VIREMIA; VIRUS MUTATION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INDIA; LAMIVUDINE; MUTATION; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE;

HEPATITIS B VIRUS;

EID: 0036836580     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10205     Document Type: Article

References (19)

1. Bartenschlager R, Junker-Niepmann M, Schaller H. 1990. The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation. J Virol 64:5324-5332.
2. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349: 20-22.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
4. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 88:8495-8499.
5. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK. 2000. Benificial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33:308-312.
6. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill A, Wong BC, Dent J, Wu PC. 1997. Lamivudine is effective in suppressing hepatitis B virus DNA in chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25:241-244.
7. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. 2000. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 32:828-834.
8. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recepients with lamivudine. Hepatology 24:711-713.
9. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
10. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, Merle P, Abidi H, Trepo C, Zoulim F. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32:1078-1088.
11. Oon CJ, Chen WN, Lim N, Koh S, Lim GK, Leong AL, Tan GS. 1999. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res 41:113-118.
12. Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F. 1999. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29:230-237.
13. Poch O, Sauvaget I, Delarue M, Tordo N. 1989. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 8:3867-3874.
14. Richman DD. 1996. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 29:31-33.
15. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP. 1999. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occuring under HBIg immunoglobulin after liver transplantation. Hepatology 30:244-256.
16. Tiollais P, Pourcel C, Dejean A. 1985. The hepatitis B virus. Nature 317:489-495.
17. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
18. Yeh CT, Chien RN, Chu CM, Liaw YF. 2000. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 31:1318-1326.
19. Zoulim F, Trepo C. 1998. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 29:151-168.